Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 8;9(2):17.
doi: 10.3390/cancers9020017.

Androgen Receptor Signaling in Salivary Gland Cancer

Martin G Dalin  1   2 , Philip A Watson  3 , Alan L Ho  4 , Luc G T Morris  5   6
Affiliations
Review

Androgen Receptor Signaling in Salivary Gland Cancer

Martin G Dalin et al. Cancers (Basel). .

Abstract

Salivary gland cancers comprise a small subset of human malignancies, and are classified into multiple subtypes that exhibit diverse histology, molecular biology and clinical presentation. Local disease is potentially curable with surgery, which may be combined with adjuvant radiotherapy. However, metastatic or unresectable tumors rarely respond to chemotherapy and carry a poorer prognosis. Recent molecular studies have shown evidence of androgen receptor signaling in several types of salivary gland cancer, mainly salivary duct carcinoma. Successful treatment with anti-androgen therapy in other androgen receptor-positive malignancies such as prostate and breast cancer has inspired researchers to investigate this treatment in salivary gland cancer as well. In this review, we describe the prevalence, biology, and therapeutic implications of androgen receptor signaling in salivary gland cancer.

Keywords: androgen receptor; androgen-deprivation therapy (ADT); salivary duct carcinoma; salivary gland cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Reported prevalence of AR splice variant expression in SDC. References: For AR-FL, [8,24,25,26,27,28,29,30,31,33,34,41,42,43,44,45]; for AR-V7, [8,26]; for AR-V3 and AR-45, [26].
See this image and copyright information in PMC

References

    1. Eveson J.W., Auclair P., Gnepp D.R., El-Naggar A.K. Pathology and Genetics of Head and Neck Tumours: International Agency for Research on Cancer. World Health Organization; Geneva, Switzerland: 2005. Tumors of the salivary glands; pp. 210–281.
    1. Terhaard C.H., Lubsen H., Van der Tweel I., Hilgers F.J., Eijkenboom W.M., Marres H.A., Tjho-Heslinga R.E., de Jong J.M., Roodenburg J.L. Salivary gland carcinoma: Independent prognostic factors for locoregional control, distant metastases, and overall survival: Results of the dutch head and neck oncology cooperative group. Head Neck. 2004;26:681–693. doi: 10.1002/hed.10400. - DOI - PubMed
    1. Renehan A., Gleave E.N., Hancock B.D., Smith P., McGurk M. Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br. J. Surg. 1996;83:1750–1754. doi: 10.1002/bjs.1800831228. - DOI - PubMed
    1. Fitzpatrick P.J., Theriault C. Malignant salivary gland tumors. Int. J. Radiat. Oncol. Biol. Phys. 1986;12:1743–1747. doi: 10.1016/0360-3016(86)90314-7. - DOI - PubMed
    1. Panwar A., Kozel J.A., Lydiatt W.M. Cancers of major salivary glands. Surg. Oncol. Clin. N. Am. 2015;24:615–633. doi: 10.1016/j.soc.2015.03.011. - DOI - PubMed

LinkOut - more resources